Clinicopathological Features and Prognostic Evaluation of UBR5 in Liver Cancer Patients

In Vivo Detection of Bile Duct Pre-Cancer With Endoscopic Light Scattering Spectroscopy

Effectiveness and Safety of Avatrombopag in Liver Cancer Patients with Severe Thrombocytopenia: Real-World Data and Challenges

Lenvatinib as Second-Line Treatment in Patients With Unresectable Hepatocellular Carcinoma: A Retrospective Analysis

Changes in Hepatic Fibrosis and Incidence of HCC Following Direct-Acting Antiviral Treatment of F3 Chronic Hepatitis C Patients: A Prospective Observational Study

Functional Imaging of Liver Cancer (FLIC): Study Protocol of a Phase 2 Trial of 18F-DCFPyL PET/CT Imaging for Patients With Hepatocellular Carcinoma

Covalent Organic Polymer Induces Apoptosis of Liver Cancer Cells Via Photodynamic and Photothermal Effects

Proteo-Genomic Characterization of Virus-Associated Liver Cancers Reveals Potential Subtypes and Therapeutic Targets

Clinicopathological Features and Prognostic Evaluation of UBR5 in Liver Cancer Patients

header-info

Nov, 28, 2022

Typically, liver cancer patients are diagnosed at an advanced stage and have a poor prognosis. N-recognin 5 (UBR5), a component of the ubiquitin protein ligase E3, is involved in the genesis and progression of several types of cancer. As of yet, it is unknown what the exact biological function of UBR5 is in liver cancer.